Status:
NOT_YET_RECRUITING
Long-term Impact of NMDAR Encephalitis, Level 3
Lead Sponsor:
Hospices Civils de Lyon
Collaborating Sponsors:
Charite University, Berlin, Germany
Conditions:
NMDAR Autoimmune Encephalitis
Eligibility:
All Genders
18+ years
Brief Summary
NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year. Patients with anti-NMDAR enc...
Eligibility Criteria
Inclusion
- Patients with NMDAR encephalitis
- Age ≥ 18 years old
- Patient affiliated to a social security system
- No opposition from the patient
- Access to an internet connection and a computer
Exclusion
- Patients whithout NMDAR encephalitis
- Patient under guardianship or curatorship
- Patient with neurological disorders pre-existing encephalitis
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07158229
Start Date
October 1 2025
End Date
October 1 2026
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de référence des syndromes neurologies paranéoplasiques et encéphalites auto-immunes - Hôpital neurologiques Pierre WERTHEIMER - Groupement hospitalier Est - Hospices civiles de Lyon
Bron, France, 69500